StockNews.AI
IONS
Benzinga
1 min

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

1. Olezarsen reduces fasting triglyceride levels by up to 72%. 2. 85% reduction in acute pancreatitis events observed with olezarsen. 3. 86% of patients achieved triglyceride levels below 500 mg/dL. 4. IONS plans to submit supplemental FDA application by year-end. 5. Shares retreated 5.21% at publication time.

5m saved
Insight
Article

FAQ

Why Bullish?

The successful results from pivotal studies support olezarsen's potential market approval, similar to past successful drug launches in severe conditions, likely driving investor confidence.

How important is it?

The article provides critical data on olezarsen, which is essential for IONS's market trajectory.

Why Long Term?

The FDA approval process may take several months, but sustained positive clinical results position IONS favorably for future revenue growth from olezarsen.

Related Companies

Related News